The substrate enters the active site and kicks water off Fe³⁺, then delivers the first electron through CPR, reducing Fe³⁺ to Fe²⁺.The catalytic cycle of CYP450 (cytochrome P450) — one of the most complex chemical cycles in the body, and most drugs pass through it to be metabolized.
Starting point: resting CYP holds one heme — an iron ion Fe³⁺, in the "low-spin" resting state:
· Substrate R-H (drug / toxin / endogenous compound) enters the active site · Substrate binds the hydrophobic pocket near Fe³⁺ → kicks water off Fe³⁺ · Fe³⁺ changes from low spin to high spin → the "ready-to-go" state
First electron injection: · Comes from -CYP reductase (CPR) — a partner flavoprotein · NADPH → CPR → single-electron transfer to Fe³⁺ · Fe³⁺ + e⁻ → Fe²⁺
Key chemistry: this step is "Fe transitioning from "resting" to "working"" — without NADPH the entire CYP system collapses.
This step takes ~ 200 ms — CYP is a slow enzyme, unlike the "seconds-scale" fast enzymes of the ETC.
2 · O₂ binding + second electron
Fe²⁺ binds O₂ and takes a second electron, then the O-O bond breaks to form Compound I, the most strongly oxidizing form of CYP.Fe²⁺ has now "softened" and can bind O₂:
· Atmospheric O₂ enters the active site · O₂ coordinates with Fe²⁺ → forms the Fe²⁺-O₂ complex · Further electron rearrangement → Fe³⁺-O₂⁻ (superoxide-like intermediate)
Second electron injection: · Again from -CPR (some CYP reactions can also borrow from cytochrome b5) · Total consumption: 2 electrons / 1 NADPH (NADPH is an electron carrier in the cell)
Forms a peroxo intermediate: Fe³⁺-O-O²⁻ — a highly reactive intermediate, about to split
O-O bond cleavage (rate-limiting): · One H⁺ joins → forms Fe-OOH (hydroperoxo) · Add another H⁺ + 1 water molecule leaves → Fe⁴⁺=O + a cation radical, the so-called "Compound I" · This is the most strongly oxidizing form of CYP — similar to the analogous reactive species in catalase / peroxidase
"Compound I" = CYP's "chemical weapon": · Extremely high oxidation potential (~ +1.0 V) · Can directly abstract H from even the least reactive C-H bonds · Can also add across π bonds (forming epoxides)
Clinical significance: · Cytochrome b5 deficiency / mutation → some CYP reactions impaired · CO poisoning = CO binds Fe²⁺ 200× more tightly than O₂ → occupies the CYP active site + occupies hemoglobin simultaneously → dual toxicity
3 · Compound I extracts H · oxidizes substrate
Compound I steals a hydrogen from the substrate and attaches a hydroxyl, making a more water-soluble R-OH, though this step often makes the molecule more toxic first.Compound I (Fe⁴⁺=O radical) now faces substrate R-H:
Step one — H-atom abstraction (radical rebound): · The oxygen radical of Compound I steals the H atom from R-H · Forms R• (carbon radical) + Fe-OH · Picosecond-scale reaction — but this instant determines the entire reaction direction
Step two — radical rebound recombination: · R• combines with the -OH on Fe-OH · Forms R-OH + Fe³⁺ · Returns to the resting state — ready for the next cycle
Net chemical equation: · R-H + O₂ + + H⁺ → R-OH + H₂O + NADP⁺
This R-OH product is the input for Phase II: · -OH is a "water-soluble handle" · It can now be conjugated by Phase II enzymes (UGT / SULT) with glucuronate / sulfate → genuinely excreted from the body
Why Phase I "frequently activates toxicity":
· Acetaminophen + CYP2E1 → NAPQI (highly toxic quinone imine) → requires GSH for neutralization; if GSH is depleted → hepatic necrosis · Benzo[a]pyrene + CYP1A1 → epoxide → covalently binds DNA → carcinogenic initiating event · Aflatoxin + → epoxide → hepatocyte DNA damage → liver cancer · Ethanol + CYP2E1 → acetaldehyde → intoxication + carcinogenesis
Key insight: CYP is not a "detox enzyme," it is a "modification enzyme." It makes hydrophobic molecules more hydrophilic, but the chemical pathway often makes them more toxic first. This is why a complete "biotransformation" requires Phase I + Phase II to work together — neither phase alone is enough.
4 · Uncoupling leakage + individual variation
Each turn of the CYP cycle leaks some oxygen as , and CYP activity varies between people, set by genes and by exposures such as smoking and grapefruit.CYP is not 100% efficient — "uncoupling" is a common but rarely discussed side reaction:
Ideal coupling: 1 + 1 O₂ → 1 R-OH (no residue)
Actual uncoupling: NADPH + O₂ are consumed, but part of the O₂ leaks as : · Pathway 1: Fe²⁺-O₂ → released as superoxide O₂⁻ · Pathway 2: peroxo intermediate → released as H₂O₂ · Pathway 3: Compound I misses the substrate → reduces to water but generates ROS byproducts
Result: every turn of the cycle leaks part of the O₂ as ROS, in a proportion that varies with substrate, enzyme and conditions.
Clinical significance:
· Long-term heavy drinking → CYP2E1 is markedly induced → more ROS → one of the mechanisms of alcoholic liver disease · The body neutralizes these ROS with its own systems such as glutathione (GSH); whether extra antioxidant supplements help has no human evidence behind it
Individual variation in CYP — a layer every prescriber has to consider:
Genetic: · CYP2D6: some people are "slow metabolizers" → codeine is not turned into morphine and does not relieve pain; a few are "ultra-rapid metabolizers" → it is turned too fast, which is dangerous for a breastfed baby when the mother takes it · CYP2C19: loss-of-function alleles (*2 / *3) are more common in East Asian populations → clopidogrel (Plavix) is under-activated in carriers, so its antiplatelet effect is weaker · : metabolizes the widest range of drugs, so it also has the most interactions · CYP1A2: see the caffeine-l-theanine story — how fast caffeine is cleared differs between people
Environmental: · Smoking → CYP1A2 ↑ + CYP1A1 ↑ → faster caffeine / theophylline clearance; rebounds after quitting · Grapefruit → blocks CYP3A4 in the gut → blood levels of some statins and other drugs rise · St John's wort → CYP3A4 ↑↑↑ → birth control pills / immunosuppressants fail · Chronic alcohol consumption → CYP2E1 ↑ → acetaminophen toxicity amplified
This is where pharmacogenomics is used most in the clinic — the same dose can give very different benefits and side effects in different people. So a new drug, a changed dose, or a change in smoking or drinking habits is worth telling your doctor or pharmacist about.